STOCK TITAN
  1. Home
  2. News
  3. PHIO

Phio Pharmaceuticals Corp. - $PHIO STOCK NEWS

Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: $PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Phio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Phio Pharmaceuticals's position in the market.

News
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
Rhea-AI Summary

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces the upcoming presentation of new data on its lead clinical product candidate, PH-762, at the Annual Meeting of the Society of Clinical Oncology (ASCO). PH-762, an INTASYL compound, is being studied in a US clinical trial for specific skin cancers. The open-label Phase 1b clinical study aims to assess safety and efficacy in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The data will be presented by Dr. Mary Spellman at ASCO in Chicago, Illinois on June 1, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
-
News
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced positive data showing that the intratumoral injection of PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells. The compound is well tolerated, supporting its ongoing clinical trial as a neoadjuvant therapy for cSCC, melanoma, or Merkel cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.69%
Tags
none
-
News
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Rhea-AI Summary
Phio Pharmaceuticals announces upcoming presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID). The company's lead clinical product candidate, PH-762, is the subject of three new dermatological posters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
News
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
Rhea-AI Summary
Phio Pharmaceuticals Corp. (PHIO) presents new data on its INTASYL™ siRNA gene silencing technology aimed at enhancing immune cells to target tumor cells effectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
conferences
-
News
National Spotlight Features Phio’s Innovative RNAi Technology Platform
Rhea-AI Summary
Phio Pharmaceuticals Corp. announces that its INTASYL platform will be showcased on a national program hosted by Dennis Quaid, airing on PBS and Fox Business Network in April. The program aims to highlight the company's innovative siRNA gene silencing technology designed to enhance immune cells' ability to combat tumor cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
none
-
News
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
Rhea-AI Summary
Phio Pharmaceuticals Corp. reported financial results for 2023 and provided business updates. They made progress with their lead product candidate PH-762, submitted IND to FDA, received clearance for trials in skin cancer, and have two patients completed treatment. They have four sites participating in the trial. They entered a collaboration agreement with AgonOx for a Phase 1 trial. They implemented cost rationalization and filed new patents. Scientific data on INTASYL compounds were presented. Financially, they had $8.5 million cash in 2023, reduced R&D and G&A expenses, and a net loss of $10.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
earnings
News
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Rhea-AI Summary
Phio Pharmaceuticals Corp. (PHIO) announced the presentation of new data at the Immunotherapy Conference in Munich. The company focuses on INTASYL™ siRNA gene silencing technology to enhance immune cells' ability to kill tumor cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.5%
Tags
none
-
News
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced the addition of three clinical trial sites for its Phase 1b study of PH-762, an INTASYL compound silencing PD-1 to enhance T cells' ability to kill cancer cells. The study aims to evaluate safety, tolerability, tumor response, and dosing for patients with skin cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
clinical trial
-
News
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
Rhea-AI Summary
Phio Pharmaceuticals Corp. announced the USPTO granted patents for RXI-185 and RXI-231, targeting age-related skin disorders like photo-aging and hyperpigmentation. The compounds aim to down-regulate MMP1 and TYR proteins, improving skin elasticity, thickening, and reducing pigmentation. The company now holds 81 patents, with a focus on INTASYL siRNA technology for cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
none
News
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Rhea-AI Summary
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b to improve natural killer (NK) cell activity for adoptive cell therapy, presenting at the 10th Immunotherapy of Cancer Conference in Germany. The data shows the potential for a more effective cell therapy for hematological malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
Stock PHIO logo
Phio Pharmaceuticals Corp.

Nasdaq:PHIO

PHIO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PHIO Stock Data

3.76M
4.55M
0.4%
11.04%
0.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MARLBOROUGH

About PHIO

phio pharmaceuticals corp., a biotechnology company, develops immuno-oncology therapeutics in the united states. it offers intasyl therapeutic platform focuses on silencing tumor-induced suppression of the immune system. the company develops ph-762 which targets the checkpoint protein pd-1 on immune cells for used in adoptive cell transfer (act); ph-804 that targets the suppressive immune receptor tigit, which is a checkpoint protein present on t cells and natural killer cells for used in act; and ph-790 which targets pd-l1 protein that keeps immune cells from attacking nonharmful cells in the body. it has collaborations with the gustave roussy and medigene ag, as well as with helmholtz zentrum mã¼nchen. the company was formerly known as rxi pharmaceuticals corporation and changed its name to phio pharmaceuticals corp. in november 2018. phio pharmaceuticals corp. was incorporated in 2011 and is headquartered in marlborough, massachusetts.